Enoblituzumab Plus MGA012 in Squamous Cell Carcinoma of the Head and Neck
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3, randomized, open-label study designed to evaluate safety and efficacy of
enoblituzumab in combination with MGA012, with and without chemotherapy, in first-line
treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and
neck (SCCHN). The study will be conducted in 2 modules, Module A (Phase 2) and Module B
(Phase 3).